Scholar Rock Sees Phase III Path For SMA Drug
Apitegromab Being Studied As Monotherapy And In Combination
While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.
You may also be interested in...
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.
With Nurtec and zavegepant in hand from Bristol, Biohaven tries for another success with a spinal muscular atrophy asset. It will move into epilepsy indications with the buyout of Channel, a subsidiary of Knopp.
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.